National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizumab (Keytruda®) is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.

NCPE Assessment Process Ongoing
Rapid review commissioned 14/08/2018
Rapid review completed 29/08/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 14/09/2018
Pre-submission consultation with Applicant 22/10/2018
Submission received from Applicant 20/12/2018
Current Status HTA assessment ongoing